Ultragenyx Pharma (RARE) Misses Q3 EPS by 1c

Ultragenyx Pharma (NASDAQ: RARE) reported Q3 EPS of ($1.87), $0.01 worse than the analyst estimate of ($1.86). Revenue for the quarter came in at $198 thousand versus the consensus estimate of $20 thousand.

For earnings history and earnings-related data on Ultragenyx Pharma (RARE) click here.

You May Also Be Interested In

• SanDisk and Micron surge as Apple confirms memory price pass-through
• JPMorgan Upgrades YDUQS Participacoes SA (YDUQ3:BZ) to Overweight
• Goldman Sachs Double Upgrades Bradsaude SA (SAUD3:BZ) to Buy